RT Journal Article
SR Electronic
T1 “Corticosteroid pulses for hospitalized patients with COVID-19: Effects on mortality”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.30.20204719
DO 10.1101/2020.09.30.20204719
A1 Ivan Cusacovich
A1 Álvaro Aparisi
A1 Miguel Marcos
A1 Cristina Ybarra-Falcón
A1 Carolina Iglesias-Echevarria
A1 Maria Lopez-Veloso
A1 Julio Barraza-Vengoechea
A1 Carlos Dueñas
A1 Santiago Antonio Juarros Martínez
A1 Beatriz Rodríguez-Alonso
A1 José-Ángel Martín-Oterino
A1 Miguel Montero-Baladia
A1 Leticia Moralejo
A1 David Andaluz-Ojeda
A1 Roberto Gonzalez-Fuentes
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.09.30.20204719.abstract
AB Background: COVID-19 has high mortality in hospitalized patients, and we need effective treatments. Our objective was to assess corticosteroid pulses’ influence on 60-days mortality in hospitalized patients with severe COVID-19, intensive care admission, and hospital stay. Methods: We designed a multicenter retrospective cohort study in three teaching hospitals of Castilla y León, Spain (865.096 people). We selected patients with confirmed COVID-19 and lung involvement with a pO2/FiO2 < 300, excluding those exposed to immunosuppressors before or during hospitalization, patients terminally ill at admission, or died the first 24 hours. We performed a propensity score matching (PSM) adjusting covariates that modify the probability of being treated. Then we used a Cox regression model in the PSM group to consider factors affecting mortality. Findings: From 2933 patients, 257 fulfilled the inclusion and exclusion criteria. One hundred and twenty-four patients were on corticosteroid pulses, and 133 were not. 30·3% (37/122) of patients died in the corticosteroid pulses group and 42·9% (57/133) in the non-exposed cohort. These differences (12·6% CI95% [8·54-16·65]) were statically significant (log-rank 4·72, p=0·03). We performed PSM using the exact method. Mortality differences remained in the PSM group (log-rank 5·31, p=0·021) and were still significant after a Cox regression model (HR for corticosteroid pulses 0·561, p= 0·039). There were no significant differences in intensive care admission rate (p=0·173). The hospital stay was longer in the corticosteroid group (p<0,001). Interpretation: This study provides evidence about treatment with corticosteroid pulses in severe COVID-19 that might significantly reduce mortality. Strict inclusion and exclusion criteria with that selection process set a reliable frame to compare mortality in both exposed and non-exposed groups. Funding: There was no funding provided.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere are no funds supporting our studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local ethics committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe can provide all data in the study if requested with a funded reason. ARDSAcute respiratory distress syndromeCOVID-19Coronavirus disease 2019ICUIntensive care unitPSMPropensity score matchingSARS-CoV-2Severe acute respiratory syndrome coronavirus 2PCRPolymerase chain reactionIFN—γInterferon-γTNF-αTumor necrosis factor αLDHLactate dehydrogenaseCRPC-reactive protein